What Happened
- Prime Minister Narendra Modi launched India's nationwide Human Papillomavirus (HPV) vaccination campaign on February 28, 2026, from Ajmer, Rajasthan.
- The programme targets approximately 1.15 crore (11.5 million) 14-year-old girls annually and provides a free single dose of the HPV vaccine at government health facilities across all states and Union Territories.
- The vaccine (Gardasil-4, a quadrivalent HPV vaccine protecting against types 6, 11, 16, and 18) will be delivered through schools using a grade-based approach (Classes 5-10), with community outreach for out-of-school girls.
- The initial campaign will run for 90 days; after completion, HPV vaccination will be incorporated into routine Universal Immunization Programme (UIP) session days.
- India joins over 160 countries that have integrated HPV vaccination into national immunisation schedules.
Static Topic Bridges
Universal Immunization Programme (UIP) — Scope and Structure
The Universal Immunization Programme (UIP) is one of the largest public health programmes in the world, providing free vaccines to children and pregnant women through government health facilities. Launched in 1985 as an expansion of the Expanded Programme on Immunization (EPI, started 1978), the UIP currently provides vaccines against 13 diseases.
- Administered by the Ministry of Health and Family Welfare; National Technical Advisory Group on Immunization (NTAGI) makes evidence-based recommendations for new vaccine introductions
- Vaccines under UIP include: BCG, OPV, Hepatitis B, DPT, Hib, Rotavirus, PCV, IPV, Measles-Rubella (MR), JE, Td, and now HPV (14-year girls)
- Mission Indradhanush (2014) — targeted immunisation drive to reach children and pregnant women missed by routine UIP, achieving 90%+ full immunisation coverage
- Intensified Mission Indradhanush (IMI) has had multiple phases (2.0, 3.0, 4.0, 5.0) to close remaining coverage gaps
- The UIP is fully centrally funded; vaccines are procured centrally by the Government of India and distributed through the cold chain system
Connection to this news: Adding HPV vaccine to the UIP is a significant expansion of the programme's scope from childhood diseases to adolescent health. It marks India's first UIP vaccine specifically targeting an infectious cause of cancer.
Human Papillomavirus (HPV) — Virology and Cancer Mechanism
Human Papillomavirus (HPV) is a group of over 200 related viruses, of which approximately 14 "high-risk" types are oncogenic (cancer-causing). HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases globally. The virus infects the squamous epithelial cells of the cervix and, in persistent infections, can cause cellular changes that progress to cervical intraepithelial neoplasia (CIN) and eventually invasive cancer over 10-20 years.
- HPV is primarily transmitted through sexual contact; most HPV infections (90%+) clear spontaneously within 2 years due to immune response
- Persistent high-risk HPV infection is the necessary (though not sufficient) cause of virtually all cervical cancers
- HPV also causes other cancers: oropharyngeal, anal, vulvar, vaginal, and penile cancers
- Gardasil-4 (quadrivalent): protects against HPV types 6 and 11 (cause ~90% of genital warts) and types 16 and 18 (high oncogenic risk)
- WHO recommends a single-dose schedule for girls aged 9-14; HPV vaccines are 93-100% effective in preventing cervical cancer caused by vaccine-covered HPV types when administered before exposure (i.e., before sexual debut)
Connection to this news: India's choice of a single-dose schedule aligns with WHO's 2022 revised guidance, which found that one dose provides robust long-term protection equivalent to two doses for girls in the 9-14 age group — making mass national programmes logistically feasible.
Cervical Cancer Burden and the National Cancer Control Framework
Cervical cancer is the second most common cancer among women in India (after breast cancer). India accounts for approximately 25% of the world's cervical cancer deaths, making it a critical public health priority. India's response operates through the National Programme for Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), expanded to the National NCD Mission.
- India records over 1.2 lakh (120,000) new cervical cancer cases and approximately 80,000 deaths annually
- Crude incidence rate: 18.7 per 100,000 women; cumulative risk: 2.0%
- Cervical cancer is the only major cancer with an entirely preventable cause (HPV infection), an effective vaccine, and an effective screening test (Pap smear / VIA — visual inspection with acetic acid)
- WHO's 90-70-90 strategy for cervical cancer elimination: 90% girls vaccinated by age 15, 70% women screened by age 35 and 45, 90% women with cervical disease treated
- India's Ayushman Bharat — Health and Wellness Centres (HWCs) include cervical cancer screening as a core service; VIA-based screening is the recommended primary screening method for India
Connection to this news: The HPV vaccination drive addresses the primary prevention pillar (vaccination) of WHO's elimination strategy. However, experts note that vaccination of 14-year-olds today will show population-level cancer reduction only after 20-30 years; interim gains require parallel investment in screening and treatment.
Women's Health, Constitutional Provisions, and State Responsibility
The right to health is a component of the right to life under Article 21. The state's obligation toward women's health is further grounded in Article 15(3) (special provisions for women and children), Article 42 (just and humane conditions of work, maternity relief), and Article 47 (duty to raise the level of nutrition and improve public health).
- Article 15(3) enables the state to make special provisions for women and children — the legal basis for women-targeted health programmes including HPV vaccination
- The 86th Constitutional Amendment (2002) inserted Article 21A (Right to Education) and also strengthened state responsibility for child welfare — often cited alongside health entitlements for adolescent girls
- National Health Policy 2017 aims to achieve Universal Health Coverage, with explicit targets for maternal and child health, and reproductive health for adolescents
- The PM launches this programme on the eve of International Women's Day (March 8), framing it as "women empowerment" — connecting vaccine access to gender equity goals
- Pradhan Mantri Jan Arogya Yojana (PM-JAY) / Ayushman Bharat covers cervical cancer treatment costs for eligible women — completing the prevention-to-treatment continuum
Connection to this news: The HPV vaccination drive is framed not just as a medical intervention but as an expression of the constitutional commitment to gender equity and women's health. Providing free, school-delivered vaccination removes economic and logistical barriers that have historically left poor and rural girls most at risk.
Key Facts & Data
- Launch date: February 28, 2026; Location: Ajmer, Rajasthan
- Target group: 14-year-old girls; approximately 1.15 crore (11.5 million) girls annually
- Vaccine: Gardasil-4 (quadrivalent HPV types 6, 11, 16, 18); single dose (0.5 ml IM, left upper arm)
- Campaign duration: 90 days, then integrated into routine UIP sessions
- India's cervical cancer burden: ~1.2 lakh new cases + ~80,000 deaths per year
- Countries with HPV in national schedules: over 160 (India joins this group)
- HPV types responsible for 70% of cervical cancers: types 16 and 18
- WHO 90-70-90 elimination targets: 90% vaccinated by 15, 70% screened twice in lifetime, 90% of cases treated
- Delivery mechanism: School-based (Grades 5-10) + community outreach for out-of-school girls
- NTAGI: National Technical Advisory Group on Immunization — the body that recommended HPV inclusion in UIP